Platform | Publications

The New England Journal of Medicine
Levin, AA. N Engl J Med 2017;376:1DOI 10.1056/NEJMcibr1613559

The New England Journal of Medicine
Levin, AA. N Engl J Med 2019;380:1DOI: 10.1056/NEJMra1705346

2022 AAN Annual Meeting

Study Design of AOC 1001-CS1, a Phase 1/2 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Patients with Myotonic Dystrophy Type 1 (DM1) (MARINA™) 

Antibody-Oligonucleotide Conjugates (AOCs) Demonstrate Potent and Durable Exon Skipping and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy

Prevalence of healthcare conditions and services used by patients with myotonic dystrophy (DM1 and DM2) prior to diagnosis; a real-world data analysis

Understanding the patients’ journey to the diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a real-world retrospective data analysis

DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOC) for the Treatment of FSHD

2022 MDA Clinical and Scientific Conference

DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOC^TM) for the Treatment of FSHD

A Phase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1 (DM1): MARINA Study Design

Understanding the patients’ journey pre- and post-diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a real-world retrospective data analysis 

Prevalence of healthcare conditions and services used by patients with myotonic dystrophy pre-and post-diagnosis, a real-world data analysis 

DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOC^™) for the Treatment of FSHD

Optimization of AOC 1001, an antibody-oligonucleotide conjugate targeting the underlying cause of myotonic dystrophy type 1

DUX4 siRNA Optimization for the Development of an Antibody Oligonucleotide Conjugate (AOC^™) for the Treatment of FSHD